Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Hayashi
Tomoko
T
aRebecca and John Moores UCSD Cancer Center bDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Chan
Michael
M
Norton
John T
JT
Wu
Christina C N
CC
Yao
Shiyin
S
Cottam
Howard B
HB
Tawatao
Rommel I
RI
Corr
Maripat
M
Carson
Dennis A
DA
Daniels
Gregory A
GA
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D016207:Cytokines / Q000378:metabolism; D004357:Drug Synergism; D005260:Female; D005434:Flow Cytometry; D007107:Immune System; D007376:Interleukin-2 / Q000378:metabolism* / Q000494:pharmacology; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism*; D008546:Melanoma, Experimental; D008562:Membrane Glycoproteins / Q000819:agonists* / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics; D009368:Neoplasm Transplantation; D010712:Phosphatidic Acids / Q000494:pharmacology*; D010743:Phospholipids / Q000494:pharmacology*; D051199:Toll-Like Receptor 7 / Q000819:agonists* / Q000378:metabolism*; D051217:Toll-Like Receptor 9 / Q000235:genetics
D000970:Antineoplastic Agents; D016207:Cytokines; D007376:Interleukin-2; D008562:Membrane Glycoproteins; C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; D010712:Phosphatidic Acids; D010743:Phospholipids; C000593719:TMX201; C477038:Tlr7 protein, mouse; C495370:Tlr9 protein, mouse; D051199:Toll-Like Receptor 7; D051217:Toll-Like Receptor 9; D000225:Adenine